Switch Launches Living Data Center EVO, Transforming AI Infrastructure and Operational Efficiency
- Switch® launched the Living Data Center (LDC) EVO, redefining data center operations for AI applications.
- The LDC EVO integrates NVIDIA's technologies for enhanced automation, real-time data, and predictive maintenance in AI environments.
- Switch's LDC EVO positions the company as a leader in optimizing AI infrastructure, driving future advancements in performance.
Revolutionizing AI Infrastructure: Switch® Unveils the Living Data Center EVO
In an era where artificial intelligence (AI) is rapidly transforming industries, Switch® addresses the growing demand for sophisticated infrastructure with the launch of its Living Data Center (LDC) EVO. This innovative system, revealed on March 16, 2026, in Las Vegas, redefines how data centers operate, moving away from traditional, human-managed environments to automated, intelligent ecosystems tailored for AI applications. By integrating the NVIDIA Omniverse DSX Blueprint within its EVO AI Factory™ framework, Switch enhances operational efficiency, enabling facilities to achieve high levels of automation and intelligence.
The integration with the NVIDIA Omniverse libraries and OpenUSD creates a comprehensive operational landscape, where every aspect of the AI factory is represented in a high-fidelity, physics-accurate 3D digital twin. Unlike conventional Data Center Infrastructure Management (DCIM) systems that struggle with the complexities of modern AI environments, LDC EVO provides continuous updates of this digital twin, ensuring that facility management is bolstered by accurate real-time data. This technological leap facilitates not only operational oversight but also predictive maintenance, thereby enhancing performance and reducing downtime in AI-centric operations.
Switch’s enhancements extend beyond virtual representation; they allow customers to execute rigorous hardware validation processes before deployment. By utilizing NVIDIA accelerated computing on Dell PowerEdge servers at extreme densities, LDC EVO ensures that configurations, such as those necessary for NVIDIA Grace Blackwell systems, are fully optimized for performance demands. Chief Technology Officer Zia Syed highlights the architecture's modularity and configurability, which supports diverse cooling systems and accommodates significant AI workloads, resulting in a more streamlined deployment process across Switch's platforms.
Impact on the AI and Data Center Landscape
The introduction of LDC EVO represents a marked shift in the operational dynamics of AI factories, spearheading advancements that are essential as more industries turn to AI for efficiency and scalability. As organizations seek to optimize their AI infrastructure, the demand for solutions that seamlessly integrate automation, intelligence, and real-time operational capabilities will surge.
Switch’s commitment to advancing AI operational capabilities through innovations like the LDC EVO positions the company as a key player in the data center sector, increasingly focused on facilitating high-performance environments for AI-driven enterprises. Such developments highlight the critical intersection of AI technology and infrastructure, paving the way for future advancements in operational efficiencies and intelligent data management.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…